CHDI
KineMed and CHDI Foundation collaborate to develop new biomarkers of disease progression and to evaluate potential therapeutics for Huntington’s disease
Emeryville, CA and New York, NY, KineMed, Inc. (www.kinemed.com) and CHDI Foundation, Inc. announced today a collaboration to use KineMed’s isotopic labeling and dynamic proteomics platform to investigate the t ...Read More
Galenea and CHDI Foundation announce collaboration to identify key synaptic dysfunction in Huntington’s disease
Cambridge, MA and New York, NY, Galenea Corp. and CHDI Foundation, Inc. have announced a collaboration to identify synaptic dysfunction linked to >Huntington’s disease (HD) utilizing Galenea’s proprietary synaptic transmission drug discovery p ...Read More
Cristina Sampaio, MD, PhD, joins CHDI Foundation as Chief Clinical Officer
New York, CHDI Foundation, Inc. has appointed Cristina Sampaio, MD, PhD, as Chief Clinical Officer. In this newly-created position Sampaio will lead and develop CHDI’s clinical programs by building both internal capabilities and further developing ...Read More
Isis and CHDI Renew Collaboration
Carlsbad, California - Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) and CHDI Foundation, Inc. announced today a renewal of their collaboration to discover and develop an antisense drug for the treatment of Huntington’s disease (HD), a fatal neurodege ...Read More
CHDI and FMI Collaboration
New York, CHDI Foundation, Inc. has entered into collaboration with the Friedrich Miescher Institute for Biomedical Research (FMI) to develop an assay to quantify huntingtin, the protein that causes Huntington’s disease (HD). FMI and CHDI will col ...Read More
Sangamo BioSciences and CHDI Foundation announce collaboration to develop ZFP Therapeutic® for Huntington’s disease
Richmond, California and New York – Sangamo BioSciences, Inc. (Nasdaq: SGMO) and CHDI Foundation, Inc. have announced a collaboration to develop a novel therapeutic for Huntington’s disease (HD) based on Sangamo’s proprieta ...Read More
SageBionetworks launches international neurobiology partnerships
Seattle, WA Sage Bionetworks has begun projects to build advanced computational models of neurobiological disease through ongoing partnerships with CHDI Foundation and Takeda Pharmaceutical Company. Analyses and the resulting models will be deposited ...Read More
CHDI Foundation, Inc. and Siena Biotech SpA enter collaboration to validate novel therapeutic targets for Huntington’s disease
New York City, NY & Siena, Italy – CHDI Foundation, Inc. (CHDI) and Siena Biotech SpA have announced a collaboration to explore and validate molecular targets that could have therapeutic potential in Huntington’s disease (HD). CHDI, a not-fo ...Read More
Enroll HD Frequently Asked Questions
By Research Participants:
- What will happen between now and July 1st 2011 – do I still attend my REGISTRY/COHORT visit? Yes. Please attend your scheduled REGISTRY or COHORT visit. Your continued ...Read More
Enroll-HD – A Prospective Registry Study in a Global HD Cohort
New York, NY; CHDI Foundation, Inc., today announced the start of a planning and consultation process to combine the existing REGISTRY and COHORT longitudinal clinical observation studies of Huntington’s disease (HD) into a worldwide initiative ca ...Read More